Skip to content

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

A Randomized Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00312117
Enrollment
300
Registered
2006-04-07
Start date
2006-01-31
Completion date
2006-02-28
Last updated
2015-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast Induced Nephropathy, Kidney Diseases

Keywords

contrast induced nephropathy, sodium bicarbonate, cardiac catheterization

Brief summary

Contrast nephropathy (CN) is a common cause of renal failure associated with prolonged hospitalization, significant morbidity/mortality, and cost. In addition, these patients may require temporary or permanent hemodialysis which, in turn, is associated with further morbidity, mortality, and cost. CN has been reported to account for 10% of hospital acquired renal failure. In recent years, studies have investigated preventive therapies with mixed results. Fenoldopam was found to be ineffective in a large randomized trial. Dopamine has been shown to be ineffective as a preventive strategy. Hemofiltration has been shown to be beneficial (New England Journal of Medicine \[NEJM\] 2003) but is costly and not practical. Mucomyst has shown mixed results. The single strategy which most would agree as being beneficial remains hydration, most commonly with intravenous 0.9% normal saline. Most recently, sodium bicarbonate has been shown to be beneficial in a small randomized trial (n=119). It is clear that the most cost effective strategies for treatment of CN should be aimed at prevention. The general question is: Is a sodium bicarbonate solution more efficacious in preventing contrast nephropathy compared to normal saline? The general hypothesis is that sodium bicarbonate will be more efficacious.

Interventions

DRUGSodium bicarbonate

Sponsors

Kaiser Permanente
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* GFR \< 60 mL/min/1.73m2. GFR will be adjusted by a correction factor as reported by our laboratory for patients self identifying as black. * \> 18 years and have at least one of the following risk factors for contrast nephropathy: diabetes (type 2), congestive heart failure, hypertension (\> 140/90), or age \> 75. * Both inpatients and outpatients will be offered enrollment.

Exclusion criteria

* Patients unable to give consent * Already receiving sodium bicarbonate solution * Undergoing emergency cardiac catheterization * Receiving a contrast agent other than Oxilan * On hemodialysis * Recent exposure to contrast within 2 days * Pulmonary edema * Active congestive heart failure * Severe valvular abnormality * Recent significant change in kidney function (\> 15% over 2d) * One kidney * Kidney transplant status

Design outcomes

Primary

MeasureTime frame
development of contrast induced nephropathy, defined by a decrease in glomerular filtration rate (GFR) by 25% or more

Secondary

MeasureTime frame
change in serum creatinine
difference in hospital duration between groups
need for hemodialysis
30 day mortality
difference of baseline to lowest GFR and highest creatinine between groups
difference in GFR and creatinine from baseline and 2-8 weeks later

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026